Genetic Information Insecurity as State of the Art.

Genetic information is being generated at an increasingly rapid pace, offering advances in science and medicine that are paralleled only by the threats and risk present within the responsible systems. Human genetic information is identifiable and contains sensitive information, but genetic information security is only recently gaining attention. Genetic data is generated in an evolving and distributed cyber-physical system, with multiple subsystems that handle information and multiple partners that rely and influence the whole ecosystem. This paper characterizes a general genetic information system from the point of biological material collection through long-term data sharing, storage and application in the security context. While all biotechnology stakeholders and ecosystems are valuable assets to the bioeconomy, genetic information systems are particularly vulnerable with great potential for harm and misuse. The security of post-analysis phases of data dissemination and storage have been focused on by others, but the security of wet and dry laboratories is also challenging due to distributed devices and systems that are not designed nor implemented with security in mind. Consequently, industry standards and best operational practices threaten the security of genetic information systems. Extensive development of laboratory security will be required to realize the potential of this emerging field while protecting the bioeconomy and all of its stakeholders.

Cryoprotectant toxicity in Caenorhabditis elegans.

We have looked at the effects of the cryoprotectant M22 upon viability in the model organism C. elegans. M22 is a well-known vitrification solution which has been successfully used in the laboratory to preserve organs destined for transplantation. M22 reduces survival of C. elegans in a concentration-dependent manner. M22 at concentrations of 10% (v/v) or higher inhibits progeny production and development. A few mutants in the ILS (insulin-like signaling) pathway of C. elegans are more resistant to the toxic effect of M22 compared to wild-type worms. Afatinib, an anti-cancer drug, protects against M22 toxicity. Afatinib by itself does not increase longevity.

Genetic suppression of cryoprotectant toxicity.

We report here a new, unbiased forward genetic method that uses transposon-mediated mutagenesis to enable the identification of mutations that confer cryoprotectant toxicity resistance (CTR). Our method is to select for resistance to the toxic effects of M22, a much-studied whole-organ vitrification solution. We report finding and characterizing six mutants that are resistant to M22. These mutants fall into six independent biochemical pathways not previously linked to cryoprotectant toxicity (CT). The genes associated with the mutations were Gm14005, Myh9, Nrg2, Pura, Fgd2, Pim1, Opa1, Hes1, Hsbp1, and Ywhag. The mechanisms of action of the mutations remain unknown, but two of the mutants involve MYC signaling, which was previously implicated in CT. Several of the mutants may up-regulate cellular stress defense pathways. Several of the M22-resistant mutants were also resistant to dimethyl sulfoxide (Me2SO), and many of the mutants showed significantly improved survival after freezing and thawing in 10% (v/v) Me2SO. This new approach to overcoming CT has many advantages over alternative methods such as transcriptomic profiling. Our method directly identifies specific genetic loci that unequivocally affect CT. More generally, our results provide the first direct evidence that CT can be reduced in mammalian cells by specific molecular interventions. Thus, this approach introduces remarkable new opportunities for pharmacological blockade of CT.